-
ALSO READ
Zydus launches Topiramate Extended-Release Capsules
Zydus Lifesciences receives USFDA approval for Febuxostat tablets
Zydus Lifesciences receives USFDA approval for Pitavastatin Tablets
Zydus Lifesciences receives USFDA approval for Acyclovir Cream
Zydus Life gets final USFDA approval for Topiramate extended-release capsules
-
Zydus Lifesciences has received final approval for Lubiprostone Capsules, 8 mcg and 24 mcg (USRLD: Amitiza Capsules) from the United States Food and Drug Administration (USFDA).
Lubiprostone capsule is indicated to treat certain types of constipation (chronic idiopathic constipation and irritable bowel syndrome with constipation). The drug will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad (India).
Lubiprostone Capsules, 8 mcg and 24 mcg had annual sales of USD 196.5 mn in the United States (IQVIA MAT, January 2023)
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Subscribe to Business Standard Premium
Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!
Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.
Download the Business Standard App for latest Business News and Market News .
RECOMMENDED FOR YOU